Key points from article :
LyGenesis, a biotechnology company, has secured $19M in funding to advance its cell therapy research.
The company's innovative approach utilises lymph nodes as bioreactors to regrow organs.
Their lead therapy, LYG-LIV-001, targets end-stage liver disease and is currently in Phase 2a clinical trials.
LyGenesis's technology holds promise for treating various conditions, including diabetes and kidney disease.
The company's mission is to revolutionise organ transplantation and improve the lives of millions.
Investors are optimistic about LyGenesis's potential to transform healthcare.
